1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > DURECT Corporation - Product Pipeline Review - 2015

DURECT Corporation - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 35 pages

DURECT Corporation - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘DURECT Corporation - Product Pipeline Review - 2015’, provides an overview of the DURECT Corporation’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of DURECT Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of DURECT Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of DURECT Corporation’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the DURECT Corporation’s pipeline products

Reasons to buy

- Evaluate DURECT Corporation’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of DURECT Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the DURECT Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of DURECT Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of DURECT Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of DURECT Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

DURECT Corporation - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
DURECT Corporation Snapshot 5
DURECT Corporation Overview 5
Key Information 5
Key Facts 5
DURECT Corporation - Research and Development Overview 6
Key Therapeutic Areas 6
DURECT Corporation - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
DURECT Corporation - Pipeline Products Glance 14
DURECT Corporation - Late Stage Pipeline Products 14
Filing rejected/Withdrawn Products/Combination Treatment Modalities 14
Phase III Products/Combination Treatment Modalities 15
DURECT Corporation - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
DURECT Corporation - Drug Profiles 18
bupivacaine hydrochloride SR 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
methylphenidate hydrochloride SR 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
sufentanil citrate 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
DUR-928 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
DURECT Corporation - Pipeline Analysis 24
DURECT Corporation - Pipeline Products by Target 24
DURECT Corporation - Pipeline Products by Route of Administration 25
DURECT Corporation - Pipeline Products by Molecule Type 26
DURECT Corporation - Pipeline Products by Mechanism of Action 27
DURECT Corporation - Recent Pipeline Updates 28
DURECT Corporation - Dormant Projects 31
DURECT Corporation - Company Statement 32
DURECT Corporation - Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35

List of Tables
DURECT Corporation, Key Information 5
DURECT Corporation, Key Facts 5
DURECT Corporation - Pipeline by Indication, 2015 7
DURECT Corporation - Pipeline by Stage of Development, 2015 8
DURECT Corporation - Monotherapy Products in Pipeline, 2015 9
DURECT Corporation - Partnered Products in Pipeline, 2015 10
DURECT Corporation - Partnered Products/ Combination Treatment Modalities, 2015 11
DURECT Corporation - Out-Licensed Products in Pipeline, 2015 12
DURECT Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2015 13
DURECT Corporation - Filing rejected/Withdrawn, 2015 14
DURECT Corporation - Phase III, 2015 15
DURECT Corporation - Phase II, 2015 16
DURECT Corporation - Phase I, 2015 17
DURECT Corporation - Pipeline by Target, 2015 24
DURECT Corporation - Pipeline by Route of Administration, 2015 25
DURECT Corporation - Pipeline by Molecule Type, 2015 26
DURECT Corporation - Pipeline Products by Mechanism of Action, 2015 27
DURECT Corporation - Recent Pipeline Updates, 2015 28
DURECT Corporation - Dormant Developmental Projects,2015 31

List of Figures
DURECT Corporation - Pipeline by Top 10 Indication, 2015 7
DURECT Corporation - Pipeline by Stage of Development, 2015 8
DURECT Corporation - Monotherapy Products in Pipeline, 2015 9
DURECT Corporation - Out-Licensed Products in Pipeline, 2015 12
DURECT Corporation - Pipeline by Top 10 Target, 2015 24
DURECT Corporation - Pipeline by Top 10 Route of Administration, 2015 25
DURECT Corporation - Pipeline by Top 10 Molecule Type, 2015 26
DURECT Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Anesthetic Effect - Pipeline Review, H2 2016

Anesthetic Effect - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Anesthetic Effect - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Anesthetic Effect - Pipeline Review, H2 2016’, provides an overview of the Anesthetic Effect pipeline landscape. The ...

Cancer Pain - Pipeline Review, H2 2016

Cancer Pain - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • November 2016
  • by Global Markets Direct

Cancer Pain - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain – Pipeline Review, H2 2016, provides an overview of the ...

Xenon Pharmaceuticals Inc. (XENE) - Financial and Strategic SWOT Analysis Review

Xenon Pharmaceuticals Inc. (XENE) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary Xenon Pharmaceuticals Inc. (Xenon) is a biopharmaceutical company which discovers and develops a pipeline of differentiated therapeutics for orphan indications. The company's pipeline products ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.